肺膜蛋白质症 (PAP) 的医疗负担
Elinor Lee1, Ali Ataya2, Cormac McCarthy3
1UCLA Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California Los Angeles, 650 Charles E. Young Drive South, 43-229 CHS, Los Angeles, CA, 90095-1690, USA. ElinorLee@mednet.ucla.edu.
Orphanet journal of rare diseases
|February 14, 2025
概括
肺膜蛋白质症 (PAP) 患者的医疗保健利用率和费用较高. 这种罕见的肺病导致伴随性疾病,手术和整体医疗费用增加,与没有PAP的个人相比.
科学领域:
- 肺部病理学 肺部病理学
- 医疗保健经济学 医疗保健经济学
- 流行病学 流行病学
背景情况:
- 肺膜蛋白质症 (PAP) 是一种罕见的肺部疾病,其特点是表面活性剂在气泡中积累.
- 了解PAP的临床和经济负担对于患者管理和资源分配至关重要.
研究的目的:
- 使用纵向索赔数据库,比较被诊断为PAP患者和匹配的对照组之间的临床和经济负担.
- 评估PAP和非PAP队列之间的共同疾病,医疗保健资源利用率 (HCRU) 和成本差异.
主要方法:
- 一个纵向的美国索赔数据库 (2009-2022) 用于识别PAP患者 (ICD-10:J84.01或ICD-9:516.0).
- 创建了一个1:4年龄,性别和地理位置匹配的对照队列.
- 人口统计,并发症 (查尔森并发症指数),手术,药物使用,HCRU和成本在两个队列中进行了比较,12个月前和后的指数日期.
主要成果:
- 分析包括2312名PAP患者和9247名匹配对照.
- 与对照组相比,PAP患者的基线并发症 (CCI) 显著增加.
- 在随访期间,PAP患者的诊断情况,手术,药物使用,急诊,门诊,住院和更长的住院时间,以及整体成本增加.
结论:
- 这项研究代表了迄今为止对PAP患者和匹配对照的最大分析.
- 与非PAP患者相比,PAP患者的医疗保健资源利用率和相关成本显著更高.
- 这些发现突显了与肺膜蛋白质瘤相关的大量临床和经济负担.
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
01:22Chronic Obstructive Pulmonary Disease
1.1K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.1K
01:20COPD: Pathogenesis and Clinical Features
226
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
226
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
165
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
165
01:29Pneumonia II: Pathophysiology
204
The pathophysiology of pneumonia involves the following steps:
204